 , Anti-HIV Agents , Anti-Infective Agents , Anti-Retroviral Agents , Antiinfectives for Systemic Use , Antiviral Agents , Antivirals for Systemic Use , Antivirals used in combination for the treatment of HIV infections , Cytochrome P-450 CYP1A2 Inhibitors , Cytochrome P-450 CYP1A2 Inhibitors (weak) , Cytochrome P-450 CYP2A6 Substrates , Cytochrome P-450 CYP2B6 Inducers , Cytochrome P-450 CYP2B6 Inducers (strong) , Cytochrome P-450 CYP2B6 Substrates , Cytochrome P-450 CYP2C9 Inducers , Cytochrome P-450 CYP2C9 Inducers (strength unknown) , Cytochrome P-450 CYP2C9 Inhibitors , Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) , Cytochrome P-450 CYP2C9 Substrates , Cytochrome P-450 CYP2D6 Inhibitors , Cytochrome P-450 CYP2D6 Inhibitors (weak) , Cytochrome P-450 CYP2D6 Substrates , Cytochrome P-450 CYP3A Inducers , Cytochrome P-450 CYP3A Substrates , Cytochrome P-450 CYP3A4 Inducers , Cytochrome P-450 CYP3A4 Inducers (weak) , Cytochrome P-450 CYP3A4 Substrates , Cytochrome P-450 CYP3A5 Substrates , Cytochrome P-450 CYP3A7 Substrates , Cytochrome P-450 Enzyme Inducers , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Substrates , Direct Acting Antivirals , Enzyme Inhibitors , Hepatotoxic Agents , Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor , Inducers of Drug Clearance , Non-Nucleoside Reverse Transcriptase Inhibitors , Nonnucleoside Reverse Transcriptase Inhibitors , Nucleic Acid Synthesis Inhibitors , OCT1 inhibitors , Pyridines , Reverse Transcriptase Inhibitors